Phase II study of haploidentical stem cell transplantation using ex vivo photodepletion of donor lymphocyte infusions to eliminate anti-host reactivity results in low relapse rates and high survival rates: Final 2 year follow-up

      Introduction: T-cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) often suffers from delayed immune reconstitution. To overcome this issue, we have developed a donor lymphocyte infusion (DLI) product (ATIR101) that uses ex vivo photodepletion to selectively prevent graft-versus-host disease, while preserving anti-infection and anti-leukemia activity.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect